$2.73 Million in Sales Expected for RedHill Biopharma Ltd (RDHL) This Quarter

Equities analysts expect that RedHill Biopharma Ltd (NASDAQ:RDHL) will post $2.73 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for RedHill Biopharma’s earnings. The lowest sales estimate is $2.60 million and the highest is $2.90 million. RedHill Biopharma reported sales of $480,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 468.8%. The company is scheduled to report its next quarterly earnings report on Tuesday, July 24th.

On average, analysts expect that RedHill Biopharma will report full-year sales of $11.55 million for the current year, with estimates ranging from $10.97 million to $12.40 million. For the next year, analysts forecast that the firm will post sales of $18.20 million per share, with estimates ranging from $15.00 million to $21.39 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow RedHill Biopharma.

RedHill Biopharma (NASDAQ:RDHL) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.50) earnings per share for the quarter, hitting the consensus estimate of ($0.50). The firm had revenue of $2.45 million for the quarter, compared to analyst estimates of $2.14 million. RedHill Biopharma had a negative net margin of 726.64% and a negative return on equity of 114.27%.

Several research firms recently weighed in on RDHL. Zacks Investment Research upgraded shares of RedHill Biopharma from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a research note on Saturday, May 12th. Nomura began coverage on shares of RedHill Biopharma in a research note on Friday, January 26th. They set a “buy” rating and a $18.00 price objective on the stock. HC Wainwright set a $36.00 price objective on shares of RedHill Biopharma and gave the stock a “buy” rating in a research note on Wednesday, May 9th. Finally, ValuEngine lowered shares of RedHill Biopharma from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 8th. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $19.95.

Large investors have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new stake in shares of RedHill Biopharma in the fourth quarter valued at approximately $170,000. ARK Investment Management LLC acquired a new stake in shares of RedHill Biopharma in the fourth quarter valued at approximately $149,000. Sabby Management LLC acquired a new stake in shares of RedHill Biopharma in the fourth quarter valued at approximately $110,000. Meitav Dash Investments Ltd. acquired a new stake in shares of RedHill Biopharma in the fourth quarter valued at approximately $244,000. Finally, Creative Planning acquired a new stake in shares of RedHill Biopharma in the fourth quarter valued at approximately $722,000. Institutional investors own 20.03% of the company’s stock.

RDHL traded up $0.08 on Wednesday, hitting $7.08. 69,999 shares of the company’s stock were exchanged, compared to its average volume of 99,159. The firm has a market cap of $148.91 million, a price-to-earnings ratio of -2.72 and a beta of 0.69. RedHill Biopharma has a twelve month low of $4.30 and a twelve month high of $11.25.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, and in-licensed/acquired drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company commercializes three gastrointestinal products in the United States, such as Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS), and acute enterocolitis and duodenal ulcers; EnteraGam, a prescription medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools; and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg, a prescription proton pump inhibitor drug product indicated for adults for the treatment of GERD, risk reduction of NSAID-associated gastric ulcer, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence, and for pathological hypersecretory conditions.

Get a free copy of the Zacks research report on RedHill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply